Human T-lymphotropic virus types I and II are retroviral infections that affect T-cells. HTLV-I was the first human retrovirus identified, isolated in 1978 from a patient with cutaneous T-cell lymphoma. A closely related virus, HTLV-II, was later isolated from a patient with hairy cell leukemia. Both viruses are highly cell associated, infect lymphocytes, and cause lifelong infections, although most of these infections remain asymptomatic. Approximately 2% to 5% of HTLV-I-infected individuals develop adult T-cell leukemia/lymphoma after a lag of 20 to 30 years. A smaller percentage develop a neurologic disease called HTLV-associated myelopathy or tropical spastic paraparesis. HTLV-II disease associations remain unclear. Both infections are thought to be spread through blood and sexual contact. FDA-licensed donor tests for HTLV infection are serologic screening assays for IgG antibody to HTLV-I and HTLV-II. FDA-licensed supplemental tests are also available.
REGULATORY UPDATE: FDA Issues New Guidance on COVID-19 Convalescent Plasma; AABB Toolkit Available
July 22, 2024
Complimentary Hot Topic Discussion to Focus on Blood Safety and Emerging Infectious Diseases
July 16, 2024
CDC Health Action Network Issues Health Advisory for Increased Risk of DENV Infections
June 26, 2024